{"prompt": "['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of', 'spirometry. Eur Respir J. 2005;26: 319-338.', 'Moy ML, Weston NA, Wilson EJ, Hess ML, Richardson CR. A pilot study of an Internet', 'walking program and pedometer in COPD. Respir Med. 2012;106:1342-50.', 'Quanjer P, Stanojevic S, Cole T, Baur X., Hall G, Enright P, et al. on behalf of the ERS', 'Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-', '95 year age range: the global lung function 2012 equations. Eur Respir J, 2012; 40:', '1324-1343.', 'Schmidt SA, Johansen MB, Olsen M et al. The impact of exacerbation frequency on', 'mortality following acute exacerbation of COPD: a registry-based cohort study. B Med J.', 'Open. 2014;4: (12): e006720', 'Serevent product information 2003. Available from', ' http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20236s1r028_serevent_lbl.pdf', 'Shu-Yi Liao, Roberto Benzo et al. Physical Activity Monitoring in Patients with Chronic', 'Obstructive Pulmonary Disease. Journal of the COPD Foundation 2014; 1: 155-165', 'Siler T, Kerwin E, Sousa A, Donald A, Rehan A, Church A, Efficacy and safety of', 'umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary', 'disease: Results of two randomized studies. Respir Med. 2015; 109:1155-63', 'Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of', \"clinically important deteriorations in COPD with umeclidinium/vilanterol. Int'l J of\", 'COPD, 2016; 11:1413-1424', 'Tashkin DP, Fabbri LM. Long acting beta-agonists in the management of chronic', 'obstructive pulmonary disease: Current and future agents. Respir Research, 2010; 11:', '149', 'Trivedi R, Richard N, Mehta R, and Church, A. Umeclidinium in patients with COPD: a', 'randomised, placebo-controlled study. Eur Respir J. 2014; 43: 72-81.', 'Watz H, Waschki B, Meyer T, Magnussen H: Physical activity in patients with COPD.', 'Eur Respir J 2009, 33:262-272.', 'Wedzicha JA, Brill SE, Allinson JP, Donalson GC. Mechanism and impact of the', 'frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC', 'Medicine, 2013; 11:181', '67']['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', '12.', 'APPENDICES', '12.1.', 'Appendix 1: Abbreviations and Trademarks', 'Abbreviations', 'AE', 'Adverse Event', 'ALT', 'Alanine transaminase', 'AST', 'Aspartate aminotransferase', 'ATS', 'American Thoracic Society', 'CAT', 'COPD Assessment Test', 'CI', 'Confidence Intervals', 'CID', 'Clinically important deterioration', 'COPD', 'Chronic Obstructive Pulmonary Disease', 'CPK', 'Creatine phosphokinase', 'CRF', 'Case Report Form', 'CV', 'Cardiovascular', 'DPI', 'Dry Powder Inhaler', 'DRE', 'Disease Related Event', 'DNA', 'Deoxyribonucleic acid', 'ECG', 'Electrocardiogram', 'eCRF', 'Electronic Case Report Form', 'eDiary', 'Electronic Diary', 'eMDI', 'Electronic Metered Dose Inhaler', 'E-RS', 'Evaluating Respiratory Symptoms- COPD Tool', 'ERS', 'European Respiratory Society', 'FEV1', 'Forced Expiratory Volume in One Second', 'FVC', 'Forced Vital Capacity', 'GCP', 'Good Clinical Practice', 'GCSP', 'Global Clinical Safety and Pharmacovigilance', 'GOLD', 'Global Initiative for Chronic Obstructive Lung Disease', 'GSK', 'GlaxoSmithKline', 'IB', 'Investigator Brochure', 'ICF', 'Informed Consent Form', 'ICS', 'Inhaled Corticosteroid', 'IEC', 'Independent Ethics Committee', 'IP', 'Investigational product', 'INR', 'International normalized ratio', 'IRT', 'Interactive Response Technology', 'ITT', 'Intent-to-Treat', 'IUD', 'Intrauterine Device', 'IUS', 'Intrauterine System', 'LABA', 'Long Acting Beta-Agonist', 'LAMA', 'Long-acting Muscarinic Receptor Antagonists', 'LDH', 'Lactate dehydrogenase', 'LTOT', 'Long Term Oxygen Therapy', '68']\n\n###\n\n", "completion": "END"}